Compass Therapeutics Inc
Research Compass Therapeutics Inc (CMPX) on Bullrun: market cap USD 455.62M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCMPX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 455.62M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 25.15M
- Free cash flow-USD 14.91M
Valuation Snapshot
latest market cap is USD 455.62M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 66.49M | -USD 49.17M | n/a | -0.43 | USD 30.64M | USD 9.83M | USD 196.79M |
| FY2024 | USD 850.00K | -USD 49.38M | -USD 44.90M | n/a | -0.37 | USD 43.48M | USD 6.63M | USD 125.23M |
| FY2023 | USD 0 | -USD 42.49M | -USD 40.65M | n/a | -0.56 | USD 24.23M | USD 1.73M | USD 148.54M |
| FY2022 | n/a | -USD 39.23M | -USD 34.34M | n/a | n/a | USD 34.95M | USD 2.94M | USD 181.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 455.62M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 957.60M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 199.84M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 198.88M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 634.74M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 319.64M | n/a | n/a | n/a |
About Compass Therapeutics Inc
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Compass Therapeutics Inc's market cap?
Compass Therapeutics Inc's market capitalization is USD 455.62M.
What does Compass Therapeutics Inc do?
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.